Navigation Links
Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
Date:1/9/2008

SAN DIEGO, Jan. 9 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive results from a single dose Phase 1a clinical trial of APD791 and the initiation of a multiple dose Phase 1b clinical trial to further evaluate the compound's safety, pharmacokinetics and pharmacodynamics. APD791 is Arena's internally discovered oral drug candidate intended for the treatment of arterial thrombosis.

The Phase 1a trial was a randomized, placebo-controlled, double-blind, single-ascending dose trial in 90 healthy male and female volunteers. Doses originally intended for study ranged from 1 mg to 160 mg, but due to excellent tolerability the maximum dose was increased to 320 mg. Doses were well tolerated, without any dose related adverse events, such that a maximum tolerated dose could not be defined despite achieving high concentrations in blood. APD791 was rapidly absorbed and exposures were generally related to dose. Terminal half-life (t1/2) of the parent plus active metabolites was also related to dose, and was approximately 11 hours at the higher doses. Dose dependent inhibition of serotonin-mediated amplification of platelet aggregation was demonstrated starting at the 1 mg dose, supporting APD791 preclinical data and establishing initial clinical validation of APD791's novel mechanism of action.

Based on the positive Phase 1a results, a Phase 1b trial was initiated. The Phase 1b trial is a randomized, placebo-controlled, double-blind, multiple-ascending dose trial in up to 50 healthy male and female volunteers between the ages of 19 and 45 years old. In addition to evaluating APD791's safety and tolerability profile, the trial will also evaluate the pharmacokinetics and pharmacodynamics of multip
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
4. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
5. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
6. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
7. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
8. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
9. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
10. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
11. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... ANGELES , Oct. 30, 2014 Migranade, ... Relief will be available to the 36 million U.S. ... a platform technology that targets the actual cause of ... medications attack pain and not the source Migranade is ... medication category. MIGRANADE Migraine Relief is available at ...
(Date:10/31/2014)... Oct. 31, 2014 Though therapies are in ... expected to show an annual increase of 16.2% over ... nearly $1 billion, according to Kalorama Information,s report, ... stem cell therapeutics that have gained or are expected ... "As drug developers tackle ever more complicated conditions, stem ...
(Date:10/30/2014)... 30, 2014 Stryker Orthopaedics, the Official Joint ... is rounding out its debut year of the relationship ... Scottsdale, AZ. This marks the eleventh tournament ... that the brand has activated on-site with the "Stryker ... fans on the importance of joint health.  ...
Breaking Medicine Technology:Game Changing Migraine Medication To Be Available November 2014 2Report: Stem Cell Technologies Market Growing 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4
... 2011 eCardio Diagnostics ( www.ecardio.com ) announces three executive ... of its clients and the patients they serve. ... year has provided us with an opportunity to expand the ... Larry Lawson, President & Chief Executive Officer. Robert ...
... Reportlinker.com announces that a new market ... Medical Devices Reports Bundle ... The Medical Devices Reports Bundle includes ... discount off the individual reports being purchased separately: ...
Cached Medicine Technology:Reportlinker Adds Medical Devices Reports Bundle 2Reportlinker Adds Medical Devices Reports Bundle 3Reportlinker Adds Medical Devices Reports Bundle 4Reportlinker Adds Medical Devices Reports Bundle 5Reportlinker Adds Medical Devices Reports Bundle 6Reportlinker Adds Medical Devices Reports Bundle 7Reportlinker Adds Medical Devices Reports Bundle 8Reportlinker Adds Medical Devices Reports Bundle 9
(Date:10/31/2014)... central to life. The last stage, when two daughter ... the dawn of cell biology in the Victorian era. ... to study this final step, when the dividing cell ... name given to this process by those early biologists, ... of a highly active and organized series of events. ...
(Date:10/31/2014)... The Memory Healer review published by DailyGossip.org ... whose father suffered from Alzheimer's disease. , In fact, ... his father's disease. His father pointed a gun and shot ... when the author of this method understood that he needed ... Memory Healer program is based on years of research. The ...
(Date:10/31/2014)... With all the preparations families carry ... they may overlook one critical area – the potential ... school performance and even behavior. Typical children’s vision screenings ... progressive vision problems, and to address this challenge, Dr. ... initiative: The Awesome Eyes Student Vision Program. , ...
(Date:10/31/2014)... increases the risk of certain types of breast cancer ... studies show. One study of more than 3,200 ... risk for estrogen receptor-negative and progesterone receptor-positive breast tumors ... long time for white women, but now we are ... John, a senior research scientist at the Cancer Prevention ...
(Date:10/31/2014)... Santa Barbara, CA (PRWEB) October 31, 2014 ... for holiday shoppers to find affordable but tasteful gifts for ... special 22nd Annual Early Bird Gift Giving Special , ... percent off when they purchase Wine Club Gift membership. ... to take advantage of this special. Besides offering discounts, Gold ...
Breaking Medicine News(10 mins):Health News:Cell division, minus the cells 2Health News:Cell division, minus the cells 3Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Study Confirms Obesity-Breast Cancer Link for Blacks, Hispanics 2Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2
... Department of Emergency Medicine has received a two-year, $150,000 ... the implementation of electronic health records in a suburban ... work of Michael Ward, MD, an assistant professor at ... year focusing on simulation modeling in operations research, working ...
... , TUESDAY, June 7 (HealthDay News) -- Imaging ... a detrimental effect on the brain, according to a new ... of the drug caused a decrease in the number of ... bodily functions, including concentration, movement coordination, pleasure, pain tolerance, memory ...
... , TUESDAY, June 7 (HealthDay News) -- People ... do relatively few surgeries are at greater risk for serious ... were more common among patients at hospitals with low surgical ... according to the study, published online June 7 in ...
... sounds, smells and events: far too much for us to ... be snagged by something startling, such as a slamming door, ... to us right then, such as locating our child among ... know that people are hard-wired to seek out and pay ...
... (HealthDay News) -- Being in a serious relationship is not ... new research suggests. In fact, a study by researchers ... times more likely to have unprotected sex than casual partners. ... nearly 70 percent of all new HIV/AIDS diagnoses among adolescents ...
... U.S. Department of Agriculture (USDA)-funded studies of mammary gland ... interest may aid breast cancer research. In an early ... C. M. Simmen of the Arkansas Children,s Nutrition Center (ACNC) ... rat mammary gland health were improved in the offspring (pups) ...
Cached Medicine News:Health News:Using simulation to model the implementation of electronic health records 2Health News:Chronic Pot Smoking Affects Brain Chemistry, Scans Show 2Health News:Joint Replacement Risks Rise at Less Experienced Hospitals 2Health News:Your attention please: 'Rewarding' objects can't be ignored 2Health News:Your attention please: 'Rewarding' objects can't be ignored 3Health News:For Gay Men, Serious Relationships Still Harbor Risks for HIV 2Health News:Mammary gland development of blueberry-fed lab animals studied 2
22 mm. Plastic, methylmethacrylate, lightweight. Supplied sterile....
Designed to insert eye spheres using spring loaded plunger. Polished finish. Overall length: 125 mm, 4.9 inches....
Size: Large. 24.50 mm by 26.00 mm. Clear lucite. Supplied sterile....
... Size: 2.3 x 6.4 x 80 ... Sponge II line designed by Harvey ... is a closed cell sponge which ... soft with rounded edges to minimize ...
Medicine Products: